Globalization in clinical drug development for sickle cell disease
Enrico Costa(Brigham and Women's Hospital), Lucio Luzzatto(Muhimbili University of Health and Allied Sciences), Léon Tshilolo(National Institute of Biomedical Research), Hubert G. M. Leufkens(Utrecht University), Russell E. Ware(Cincinnati Children's Hospital Medical Center), Julie Makani(Muhimbili University of Health and Allied Sciences)
Cited by 6
Related Papers
Management of Sickle Cell Disease
|JAMA|2014|1.6k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Natural History of Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|1995|900
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
|Blood|2007|578
Management of Sickle Cell Disease Summary of the 2014 Evidence-Based Report by Expert Panel Members
|Survey of Anesthesiology|2015|270